The race to catch KRAS

How pancreatic cancer's 'greasy ball' paved way to the most promising drug in decades ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

April 21, 2026 Check out STAT+

Sponsored By

Hello. We're running a limited-time deal that gets you 60% off your first year of STAT+. If you've been on the fence about getting unlimited access to our biopharma and public health policy coverage, unlocking exclusive newsletters, and gaining special access to our events, now is your moment. Discount offer is here, and thanks for reading! –Alexa Lee, newsletter strategist

Chantal Heijnen for STAT STAT+ | The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades Daraxonrasib, a pancreatic cancer drug from Revolution Medicines, is showing unprecedented success. For patients like Leanna Stokes, survival time doubled. By Angus Chen STAT+ | AACR 2026: More strong data for Revolution Medicines’ KRAS drug On the first day of AACR's 2026 annual meeting, Revolution Medicines delivered data for zoldonrasib, which targets lung cancers. By Angus Chen, Matthew Herper, and Damian Garde STAT+ | At AACR, a provocative use of CAR-T, Merck’s new thing and cancer’s geography problem At AACR, a bold use of CAR-T raises hopes and questions in smoldering multiple myeloma, plus news about Merck, rural health, and AI. By Angus Chen, Damian Garde, and Matthew Herper Adobe STAT+ | In early trial, CAR-T results raise hope of preventing multiple myeloma in high-risk patients Every patient who received the trial treatment no longer had detectable myeloma cells in their body, but researchers note it's an early, small-scale trial. By Angus Chen

More around STAT

---

In case you missed it For Ben Sasse, Revolution Medicines’ pancreatic cancer trial felt like his best, only option, STAT After a year of turmoil, cancer researchers see promising signs for mRNA vaccines, CNN Where U.S. science has been hit hardest after Trump’s first year, Washington Post

---

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser